A Study in Healthy Men to Measure the Amount of BI 730357 in the Blood When Taken as a Tablet

Phase 1 Completed 6 enrolled Boehringer Ingelheim

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To investigate the absolute oral bioavailability of BI 730357 administered as tablet compared with \[C-14\]BI 730357 BS administered as intravenous microtracer

Timeline

Start: 2019-01-31
Primary completion: 2019-03-26
Completion: 2019-03-26

Publications

Ooi QX, Kristoffersson A, Korell J, Flack M, L Plan E, Weber B. Bounded integer model-based analysis of psoriasis area and severity index in patients with moderate-to-severe plaque psoriasis receiving BI 730357. CPT Pharmacometrics Syst Pharmacol. 2023 Jun;12(6):758-769. doi: 10.1002/psp4.12948. Epub 2023 May 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BI 730357	Unknown	—	Oral

Indications

No indication recorded.